• 
• 
• 

FDA News and Drug Updates

Braftovi Plus Mektovi a New Combination for Unresectable or Metastatic Melanoma with BRAF Mutation

FDA Approves 2 New Biosimilars for Patients with Cancer

FDA News - September 2018

A Dynamic FDA Has Led to More Rapid Cancer Drug Development

Adverse Effects

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

Meg Barbor, MPH

Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer

Adverse Events Associated with Checkpoint Inhibitors

Alice Goodman

View All Supportive Care Articles

Immunotherapy

Nivolumab-Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer

Building on the Successes of Cancer Immunotherapy

Charles Bankhead

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

View All Breast Cancer Articles

Conference Correspondent

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference

Silent Patients Find Their Voices Through an Advocate’s Journey

View All Conference Correspondent Articles

Most Popular Articles

The Pharmacist’s Role in Improving Quality in Oncology

Meg Barbor, MPH

TOP - November 2018, Vol 11, No 3 - HOPA 2018 Highlights

Oral Toxicities Associated with Cancer Therapies: What's Old Is New Again

Meg Barbor, MPH

JHOP Web Exclusives - Drug Therapies

Building on the Successes of Cancer Immunotherapy

Charles Bankhead

JHOP Web Exclusives - Immunotherapy

CAR T-Cell Therapy: Can We Afford the Cure?

Meg Barbor, MPH

TOP - November 2018, Vol 11, No 3 - HOPA 2018 Highlights

Timing of Palliative Care Consults Affects Healthcare Utilization in Elderly Patients with Pancreatic Cancer

Chase Doyle

TOP - November 2018, Vol 11, No 3 - HOPA 2018 Highlights